


Ultima PC

Sirolimus Eluting Coronary Stent System

New generation DES providing synergy of biodegradable polymer with microporous surface to enhance optimal performance



Less Polymeric Load Compared To Other DES

One million pores per cm² with average depth of 2 μm ensures optimum drug release with minimal use of polymer

Shellac Resin (Wax-Free) ensures better polymer- drug binding with negligible polymer flaking during stent expansion

Drug and Polymer are co-released in 30 days

Better Endothelialisation & Superior Strut Coverage

Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue

No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

Ultima PC

Sirolimus Eluting Coronary Stent System

Ordering Information

Length Ø (mm)	Diameter (mm)							
	2.00 mm	2.25 mm*	2.50 mm	2.75 mm	3.00 mm	3.50 mm	4.00 mm	
8.00	UAPC2008	UAPC2208	UAPC2508	UAPC2708	UAPC3008	UAPC3508	UAPC4008	
12.00	UAPC2012	UAPC2212	UAPC2512	UAPC2712	UAPC3012	UAPC3512	UAPC4012	
16.00	UAPC2016	UAPC2216	UAPC2516	UAPC2716	UAPC3016	UAPC3516	UAPC4016	
18.00	UAPC2018	UAPC2218	UAPC2518	UAPC2718	UAPC3018	UAPC3518	UAPC4018	
21.00	UAPC2021	UAPC2221	UAPC2521	UAPC2721	UAPC3021	UAPC3521	UAPC4021	
24.00	UAPC2024	UAPC2224	UAPC2524	UAPC2724	UAPC3024	UAPC3524	UAPC4024	
28.00	UAPC2028	UAPC2228	UAPC2528	UAPC2728	UAPC3028	UAPC3528	UAPC4028	
32.00	UAPC2032	UAPC2232	UAPC2532	UAPC2732	UAPC3032	UAPC3532	UAPC4032	
36.00*	-	-	-	UAPC2736	UAPC3036	UAPC3536	UAPC4036	
40.00	-	-	-	UAPC2740	UAPC3040	UAPC3540	UAPC4040	
44.00*	-	-	-	UAPC2744	UAPC3044	UAPC3544	UAPC4044	
48.00*	-	-	-	UAPC2748	UAPC3048	UAPC3548	UAPC4048	

* Please contact our Customer Care for available sizes. # Sizes Not CE Approved

COMPLIANCE CHART

Balloon Diameter Ø (mm)	Inflation Pressure (bar/10 ⁵ Pa)																			
	6	7	8	9	10	NP (Nominal Pressure)	12	13	14	15	RBP (Rupture Balloon Pressure)	17	18	19	20					
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29					
Ø 2.25	2.08	2.11	2.14	2.18	2.21	2.25	2.28	2.31	2.35	2.38	2.42	2.45	2.48	2.52	2.55					
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81					
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04					
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33					
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88					
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46					

TECHNICAL DATA

Cobalt Chromium Alloy (L605)			
Crossing Profile (Ø 2.5 mm)	0.035" / 0.889 mm	Entry Profile	0.016" / 0.406 mm
Strut Thickness	0.0027" / 68 μm (SV)	Proximal Shaft Diameter	1.9 F
	0.0031" / 79 μm (MV)	Distal Shaft Diameter	2.7 F
Balloon Marker Material	Platinum / Iridium	Recommended Guide Wire	0.014"
		Guiding Catheter	min. 5 F

CE 1434

EC REP

Manufactured By:
Translumina Therapeutics LLP
Plot No. #12, Pharmacy, Selaqui, Dehradun 248011
(Uttarakhand) India
Drug Manufacturing License No. MFG/MD/2019/000227

Registered Office:
Translumina Therapeutics LLP
Ground Floor, Metro Tower, LSC MOR Land,
New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:
Translumina GmbH
Neue Rottenburger Strasse 50,
D-72379 Hechingen, Germany

CMC Medical Devices & Drugs S.L.
C/HoracioLengo Nº 18, CP 29006, Málaga - Spain
Tel: +34951214054 Fax: +34952330100
Email: info@cmcmedicaldevices.com
www.cmcmedicaldevices.com

Customer Care No.: 011-28742874
Email: info@translumina.in
Visit www.translumina.in for more details.

Please refer to the **Instructions for Use** supplied with these devices for indications, contraindications, adverse effects, suggested procedures, warnings and precautions.

Doc. Ref. No.: UAPC.BC.04-23.Rev.00

Ultima PC

Sirolimus Eluting Coronary Stent System

translumina
LIMITLESS POSSIBILITIES




Ultimate Trackability For Treating Complexity

Ultima PC

Sirolimus Eluting Coronary Stent System

Reliable Deliverability for Consistent Excellent Performance



Ideal Flexible Approach

Ultima PC offers new generation delivery system with 'Flexi' platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Ultima PC with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability justifying its use for the most tortuous vessels.



Ultima PC

Sirolimus Eluting Coronary Stent System

10 YEARS

CLINICAL DATA OF EFFICACY & SAFETY

At 10 years, PC has shown the lowest rate of Definite/Probable Stent Thrombosis and numerically lower TLR rates as compared to permanent polymer DES with better efficacy results.



Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.

*As per Clinical data with SS stent using similar microporous surface and drug coating technology

Ultima PC


Sirolimus Eluting Coronary Stent System

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from 3 randomised trials




At 4 years, Biodegradable Polymer DES Ultima PC showed significantly lower rates of Stent Thrombosis compared to Durable Polymer SES in patients with Diabetes Mellitus.



Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials

EuroIntervention

At 4 years, Biodegradable Polymer DES compared to Durable Polymer SES demonstrated improved overall clinical outcome, reduced need for revascularisation as well as lower incidence of cardiac death or MI and reduced stent thrombosis in patients with STEMI.



Definite or probable stent thrombosis for the pooled population in each of the treatment groups. CI: confidence interval; HR: hazard ratio